These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2005-005794-29 Traitement des syndromes myélodysplasiques par l'association aracytine et bortezomib not-yet-due
Ongoing 2007-000246-13 A phase II study of the efficacity and the safety of lenalidomide in subjects with intermediate or the high risk myelodysplastic syndromes (MSD) associated with a deletion (Del) 5q[31] not-yet-due
Exempt 2007-002212-26 A Phase I/II Study of Vorinostat in Combination with Low Dose Ara-C for Patients with Intermediate-2 or High Risk Myelodysplastic Syndromes not-yet-due
Ongoing 2008-000470-21 A Phase II study of Decitabine in patients with Chronic Myelomonocytic Leukemia not-yet-due
Completed, but no date 2008-004541-29 A phase II Study of Azacitidine (Vidaza®) combined to Epoetin beta (NeoRecormon®) in IPSS low-risk and intermediate-1 MDS Patients, resistant to ESA bad-data
Exempt 2008-005999-28 PHASE I-II TRIAL OF ERLOTINIB IN HIGHER RISK MYELODYSPLASTIC SYNDROME not-yet-due
Completed, but no date 2008-006032-36 A phase ii study of the efficacy and safety of lenalidomide combined to escalating doses of chemotherapy in intermediate-2-or high risk MDS and AML with del 5 q31 bad-data
Completed, but no date 2008-008262-12 A phase II study evaluating the efficacy and safety of Lenalidomide (Revlimid®) with or without Epoetin beta (NeoRecormon®) in transfusion-dependent ESA-resistant patients with IPSS low- and intermedi... bad-data
Not reported 2009-011160-11 A phase II study of the efficacy and safety of lenalidomide combined to azacitidine in intermediate-2 or high risk MDS AND AML with del 5q 2016-07-25 due-trials
Ongoing 2009-011161-87 Treatment of anemia in myelodysplastic syndromes low risk with epoetin beta with Analysis of impact on quality of life and functional capacity not-yet-due
Exempt 2009-013404-32 A Phase I/II Multicenter Study of IV Clofarabine In Patients with High-Risk Myelodysplastic Syndrome who have failed Therapy with Azacitidine: the NIDEVOL study not-yet-due
Exempt 2009-017178-19 A phase I-II study of the efficacy and safety of Idarubicin combined to Azacitidine in int-2 or high risk myelodysplastic syndromes 2016-05-09 not-yet-due
Exempt 2010-019709-41 A phase I study of azacitidine with Ceplene/interleukin-2 followed by a randomized phase II study of the efficacy and safety of maintenance treatment with azacitidine with or without Ceplene/interleuk... not-yet-due
Exempt 2010-020341-27 A phase I/II study of the efficacy and safety of an intensified schedule of Azacitidine (Vidaza®) in intermediate-2 and high risk MDS patients not-yet-due
Exempt 2012-003120-21 A phaseI-II trial of acadesine in ipss high and int 2 myelodysplastic syndromes, acute myeloid leukemia with 20-30% marrow blasts and chronic myelomonocytic leukemia type 2 not responding to azacitidi... not-yet-due
Not reported 2014-000098-38 A phase II trial of SGI-110 in patients with ipss high and int 2 myelodysplastic syndrome, acute myeloid leukemia with 20-30% marrow blasts and chronic myelomonocytic leukemia type 2 not responding to... 2018-04-23 due-trials
Listed as ongoing, but also has a completion date 2014-000200-10 A Randomized Phase III study of Decitabine (DAC) with or without Hydroxyurea (HY) versus HY in patients with advanced proliferative Chronic Myelomonocytic Leukemia (CMML) 2021-08-16 bad-data
Other 2017-000812-41 A RANDOMIZED TRIAL TESTING EARLY VERSUS LATE ONSET OF EPO ALFA TREATMENT IN LOWER RISK MDS WITH NON RBC TRANSFUSION DEPENDENT ANEMIA AND WITHOUT DEL 5Q Etude randomisée évaluant l’introduction préc... not-yet-due
Ongoing 2017-003681-27 A single-arm phase II multicenter study of IDH1 (AG 120) inhibitor in patients with IDH1 mutated myelodysplastic syndrome Studio multicentrico di fase II a singolo braccio dell'inibitore di IDH1 (A... not-yet-due
Ongoing 2018-001693-25 A single-arm phase II multicenter study of IDH2 (AG 221) inhibitor in patients with IDH2 mutated myelodysplastic syndrome not-yet-due
Other 2019-003685-40 A PHASE II PROSPECTIVE STUDY “GFM-DACORAL-DLI” ASTX727 AND DONOR LYMPHOCYTE INFUSIONS (DLI) AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO SCT) IN VERY HIGH RISK MDS OR AML PATIENTS Étude prospe... not-yet-due
Ongoing 2020-003400-13 A Phase 2, Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloi... not-yet-due
Exempt 2021-000596-37 A randomized phase I/ II multicenter study evaluating combination of luspatercept in LR-MDS without RS having failed or being ineligible to ESA Étude multicentrique de phase I/II randomisée évaluan... not-yet-due
Other 2021-002007-35 Phase II study with safety run-in of Azacitidine (AZA) combined with Venetoclax (VEN) in patients with higher-risk Chronic Myelomonocytic Leukemia (CMML) Étude de phase II avec phase pilote de tolé... not-yet-due